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Salt-sensitivity is a major factor in the development of hypertension. The brain orexin system 
has been observed to play a role in numerous hypertensive animal models. However, orexin’s 
role in the pathology of salt-sensitive hypertension (SSH) remains to be adequately explored. 
We assessed the impact of orexin hyperactivity in the pathogenesis of the deoxycorticosterone 
acetate (DOCA) – salt rat model, specifically through modulation of Arginine Vasopressin 
(AVP). Adult male rats were separated into three groups: vehicle control, DOCA-salt, and 
DOCA-salt+OX1R-shRNA. DOCA-salt rats received subcutaneous implantation of a 21-day 
release, 75 mg DOCA pellet in addition to saline drinking water (1% NaCl and 0.2% KCl). 
DOCA-salt+OX1R-shRNA rats received bilateral microinjection of AAV2-OX1R-shRNA into 
the paraventricular nucleus (PVN) to knockdown function of the Orexin 1-Receptor (OX1R) 
within that area. Following 2-week to allow full transgene expression, a DOCA pellet was 
administered in addition to saline drinking solution. Vehicle controls received sham DOCA 
implantation but were given normal water. During the 3-week DOCA-salt or sham treatment 
period, mean arterial pressure (MAP) and heart rate (HR) were monitored utilizing tail-cuff 
plethysmography. Following the 3-week period, rat brains were collected for either PCR 
mRNA analysis, as well as immunostaining. Plasma samples were collected and subjected 
to ELISA analysis. In line with our hypothesis, OX1R expression was elevated in the PVN of 
DOCA-salt treated rats when compared to controls. Furthermore, following chronic knockdown 
of OX1R, the hypertension development normally induced by DOCA-salt treatment was 
significantly diminished in the DOCA-salt+OX1R-shRNA group. A concurrent reduction in 
PVN OX1R and AVP mRNA was observed in concert with the reduced blood pressure 
following AAV2-OX1R-shRNA treatment. Similarly, plasma AVP concentrations appeared to 
be reduced in the DOCA-salt+OX1R-shRNA group when compared to DOCA-salt rats. These 
results indicate that orexin signaling, specifically through the OX1R in the PVN are critical for 
the onset and maintenance of hypertension in the DOCA-salt model. This relationship is 
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INTRODUCTION
Hypertension is a major pathological condition that impacts 
roughly one-third of adults in the United States, with implications 
in the development of further cardiovascular complications 
such as cardiac ischemia, heart failure, and stroke (Centers 
for Disease and Prevention, 2011). Together, these conditions 
comprise the leading cause of death among adults in the 
United  States. Further studies have shown that the majority 
of hypertensive individuals are observed to have impaired 
sodium handling, resulting in enhanced pressor response 
following a salt challenge (Weinberger et al., 1986; Weinberger, 
1996; Choi et  al., 2015). This condition is known as salt-
sensitive hypertension (SSH) and is estimated to effect 
approximately half of individuals with diagnosed primary 
hypertension, not including those individuals who remain 
undiagnosed (Weinberger, 1996; Choi et  al., 2015). As salt 
intake increases, the relevance of this disease has become more 
apparent, leading numerous researchers to assess the underlying 
mechanisms mediating this hypertensive response.
Since its discovery in 1998 by two groups concurrently (de 
Lecea et al., 1998; Sakurai et  al., 1998), orexin has come under 
the spotlight as a potential regulator of feeding, sleep/wake 
cycles, in addition to blood pressure regulation. Orexin A 
(OXA) and orexin B (OXB) are the two subtypes of orexin 
neuropeptides derived from a single precursor, and while they 
both carry out their functions on G protein coupled receptors 
Orexin Receptor 1 (OX1R) and Orexin Receptor 2 (OX2R), 
OX1R has a much higher affinity for OXA than OXB. Although 
OXA and OXB producing neurons are found solely in the 
lateral hypothalamic area (LHA; de Lecea et  al., 1998; Sakurai 
et  al., 1998), their neuronal projections densely innervate 
numerous areas of the brain including the hypothalamus, brain 
stem, limbic system, as well as the circumventricular organs 
(CVOs; Peyron et  al., 1998; Nambu et  al., 1999; Kilduff and 
Peyron, 2000). Interestingly, orexin producing neurons densely 
innervate their respective receptors in the paraventricular nucleus 
(PVN; Trivedi et  al., 1998; Li and Nattie, 2014), a major area 
of cardiovascular control. Samson et  al. (1999) were some of 
the first to observe a dose-dependent increase in mean arterial 
pressure (MAP) following intracerebroventricular (ICV) injection 
of OXA and OXB in Sprague Dawley (SD) rats. Others confirmed 
these results, but also observed an increase in sympathetic 
nerve activity (SNA) following injection, indicating that orexin 
exerts its influence on the cardio vasculature through sympathetic 
activation (Shirasaka et al., 1999; Li and Nattie, 2014). Further, 
Schwimmer et  al. (2010) observed an attenuated resting blood 
pressure following genetic knockdown mRNA of the orexin 
precursor, prepro-orexin. The observed role of orexin 
hyperactivity in hypertension were replicated in subsequent 
studies in animal models of primary hypertension including 
the BPH/2J mouse (Marques et al., 2011), and the Spontaneously 
Hypertensive rat (SHR; Lee et  al., 2013, 2015; Li et  al., 2013), 
where central or orally administered orexin receptor antagonists 
resulted in attenuated blood pressure responses.
To the best of our knowledge, so far, no study has been 
conducted assessing the role of orexin in the development 
of SSH in other group. Our recent studies have shown that 
proinflammatory cytokine (PIC) activity is augmented in the 
PVN of Dahl-Salt (Dahl-S) Sensitive rats, but not in normal 
SD rats (Fan et  al., 2018). This effect was similarly observed 
following PVN injection of OXA in SD rats, which resulted 
in heightened sympathetic outflow. Furthermore, Huber et  al. 
(2017) observed that a high-salt diet in Dahl-S rats results 
in increased central orexin signaling, in addition to Arginine 
Vasopressin (AVP) production, resulting in an increase in 
blood pressure. Importantly, this effect was attenuated following 
OX1R blockade in the PVN, while sympathetic outflow 
remained unchanged (Huber et  al., 2017). The significant 
reduction in blood pressure, but not sympathetic outflow, 
indicates that orexin may regulate SSH development through 
regulation of AVP.
The importance of the PVN in AVP production and 
cardiovascular regulation has led us to believe that this 
may be  the primary pathway utilized in orexin regulation 
of SSH. However, in order to extend and replicate this work, 
further SSH rat models must be utilized. Deoxycorticosterone 
acetate (DOCA) administration to SD rats, in addition to 
salt intake has been shown to elicit an increase in blood 
pressure, which is maintained at a heightened level, specifically 
through AVP overactivity (Yu et  al., 2001). This model is 
also marked by enhanced Renin-Angiotensin-System (RAS) 
activity, resulting in endocrine dysfunction, as well as 
sympathetic hyperactivity. Only one study to date has assessed 
orexin system activity in DOCA-salt rats. Hernandez et  al. 
(2018) observed increased expression of orexin components 
within the hypothalamus, similar to our own results. However, 
this study did not assess the impact of orexin receptor 
activity in the PVN, nor did it review AVP as a potential 
mediator of the hypertensive response observed in the 
DOCA-salt model.
To this end, the present study aims to assess the role of 
PVN orexin overactivity in the pathology of DOCA-salt 
hypertension with the hypothesis that overactive orexin activity 
within the PVN will result in greater PVN AVP expression 
as well as blood AVP release, and increased blood pressure. 
Further, we  hypothesize that knockdown of OX1R function 
in the PVN will attenuate this pressor response.
mediated, at least in part, through orexin activation of AVP producing neurons, and the 
subsequent release of AVP into the periphery. Our results outline a promising mechanism 
underlying the development of SSH through interactions with the brain orexin system.
Keywords: orexin, hypertension, deoxycorticosterone acetate, vasopressin, paraventricular nucleus, blood pressure
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MATERIALS AND METHODS
Animals
All rats used in this study were purchased from Charles River 
Laboratories (Wilmington, MA). Adult male rats (200–350  g) 
were placed into three groups: DOCA-salt, DOCA-salt+OX1R-
shRNA, and vehicle control. The DOCA-Salt group received 
implantation of a 21-day release DOCA pellet (75 mg, Innovative 
Research of America, FL, United  States), and saline drinking 
solution (1% NaCl and 0.2% KCl) with normal chow for 
21  days. DOCA-salt+OX1R-shRNA rats received a PVN 
microinjection of AAV2-OX1R-shRNA (University of Florida) 
2  weeks prior to DOCA and high salt diet administration, 
identical to the DOCA-Salt group. We  elected to omit 
uninephrectomy from the procedure in order to attain a more 
gradual, modest increase in blood pressure that more closely 
mimics the development observed in humans (Kandlikar and 
Fink, 2011). The vehicle controls were given sham surgeries 
for pellet implantation, and normal water and chow. During 
the 3  weeks of treatment, blood pressure measurements were 
taken on DOCA-salt, DOCA-salt+OX1R-shRNA, and control 
rats. Following this, rats were euthanized and used for PCR, 
immunostaining, plasma, and heart weight measurements. The 
time of euthanization was confined to early afternoon, between 
approximately 2:00 and 5:00 pm, in order to mitigate the chance 
of any variability in measured physiological parameters due 
to the natural fluctuations of orexin activity throughout the 
day. All rats were housed at a constant temperature and a 
12:12  h light dark cycle and given their respective diets ad 
libitum. All animal experiments were performed in adherence 
to protocols approved by the Michigan Technological University 
Institutional Animal Care and Use Committee (IACUC).
Hypothalamic Paraventricular Nucleus 
Microinjections
Prior to any diet or DOCA treatment, DOCA-salt+OX1R-shRNA 
rats were subjected to bilateral PVN microinjection of AAV2-
OX1R-shRNA. The AAV viral vector was packaged in the 
University of Florida Viral Vector Center. Briefly, a synthetic 
complementary DNA (cDNA) oligonucleotide encoding shRNA 
targeting OX1R mRNA (CTACTTCATTGTCAACCTGT) was 
cloned into an AAV vector, PTR-UF11, under the control of 
human U6 promoter. A green fluorescence protein (GFP) 
reporter gene under the control of CBA promoter was cloned 
upstream of the shRNA expression cassette in order to directly 
visualize expression from the vector after delivery, generating 
construct AAV-OX1R-shRNA. The constructs were packaged 
into the AAV2, and virus production and titers were determined 
as previously described (Hauswirth et  al., 2000). Rats were 
anesthetized using 5% isoflurane for induction, and 2–3% 
isoflurane exposure for maintenance of anesthesia. Following 
complete anesthesia, rat heads were fixed in a stereotaxic frame. 
Two holes were drilled through the skull at coordinates of 
the PVN so that a single glass microinjector pipette could 
be  lowered into the PVN area. The coordinates for the PVN 
(in mm) were as follows: −1.6 caudal to bregma, 0.5–0.7 lateral 
to the midline, and 7.2 deep. Once the microinjector was in 
place, 200  nl of AAV2-OX1R-shRNA was injected bilaterally 
into the PVN. Approximately 10–12  min was taken between 
injections to allow for diffusion of the viral vector. Following 
injection, the wound was sutured, and rats were given a 
subcutaneous injection of a cocktail solution of meloxicam, 
penicillin, and sterile 0.9% saline the day of injection, as well 
as 2 days after in accordance with IACUC and ACF standards. 
DOCA-Salt OX1R-shRNA rats were given 2  weeks to recover 
as well as to allow full viral expression, before any other 
procedures were performed.
DOCA Pellet Implantation
DOCA-salt and DOCA-salt+OX1R-shRNA groups were 
subjected to subcutaneous implantation of a DOCA pellet 
(75  mg, 21-day release, Innovative Research of America, FL, 
United States) prior to beginning the high salt drink treatment. 
Rats were given 5% isoflurane for anesthesia induction followed 
by 2–3% isoflurane to maintain adequate anesthesia during 
the procedure. An incision was made in the retro-scapular 
region, and the DOCA pellet was placed subcutaneously. The 
wound was sutured, and rats were given the same post-
operative care as above. However, directly following the 
procedure, all rats’ drinking water was switched to a saline 
solution (1% NaCl and 0.2% KCl) for the remainder of the 
21 days. As previously mentioned, DOCA treatment is usually 
paired with uninephrectomy to exacerbate the development 
of hypertension. However, we  decided to exclude the kidney 
removal following a previously established model (Kandlikar 
and Fink, 2011) to obtain a more gradual progression of 
hypertension development that more closely mimics that seen 
in a humans, as well as to eliminate many of the adverse 
effects that traditional DOCA-salt and uninephrectomy incurs 
(Gavras et  al., 1975; Wada et  al., 1995; Loch et  al., 2006).
Blood Pressure Measurement
A subset of each group was subjected to blood pressure 
measurement during their treatment period using tail 
plethysmography (Kent Scientific, CT, United  States). DOCA-
salt, DOCA-salt+OX1R-shRNA, and control rats were all 
acclimated to the procedure for a week before measurements 
began through everyday blood pressure measurements, as 
recommended by the American Heart Association (Kurtz et al., 
2005). Briefly, rats were placed in a plastic cylinder with a 
dark nose-cone, to reduce vision and anxiety. After 10  min 
of acclimation, the tail cuff apparatus including the occlusion 
cuff and volume pressure recording cuff were placed on the 
animal for an additional 5–10  min. Artificial heating was also 
applied to maintain adequate blood flow to the tail. Following 
this, blood pressure recording began, and 10 acclimation cycles 
followed by 20 measurement cycles were conducted. Following 
blood pressure recording, averages of the 20 measurement 
cycles were taken and paired with their group to obtain a 
group mean, which was utilized for statistical analysis. Rats 
maintained acclimation during the 18-day treatment by daily 
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20-min sessions in the rat holder/tail cuff apparatus for every 
rat, to reduce variability and anxiety among the rats.
Tail-cuff plethysmography can be attributed to stress-related 
fluctuations in blood pressure, due to confinement in a small 
cylinder for extended periods of time, which may lead to 
variability of results. However, all necessary precautions were 
taken to mitigate this effect. Namely, acclimation to the cylinders 
as well as the occlusion/volume pressure recording apparatus 
began 2  weeks prior to any actual blood pressure recording 
was performed. Following 1 week of acclimation, blood pressure 
measurements were taken to identify when the blood pressure 
reached a normotensive level in all treatment groups. Once 
the blood pressure appeared to maintain a consistent, 
normotensive pressure, the experiment was initiated. In addition, 
blood pressure recording sessions were done during the same 
time every day (12:00–4:00 pm), to mitigate circadian influences 
on orexin system function, and thus to alleviate any fluctuations 
in blood pressure that may naturally occur with differential 
orexin system activity throughout the day. Furthermore, during 
the 3  weeks of blood pressure recording, acclimation was 
maintained on days when blood pressure measurements were 
not taken by daily exposure to both confinements in the 
cylinder as well as attachment of the occlusion/volume pressure 
recording apparatus for 20  min.
Real-Time PCR and Immunostaining
Following 3  weeks of treatment, rats were euthanized and 
subjected to either real time polymerase chain reaction (PCR) 
analysis to assess mRNA expression or immunostaining to 
visualize protein levels of the genes of interest in the PVN. 
For PCR, brains were removed and immediately flash frozen 
in liquid nitrogen. Following flash freezing, all brains were 
placed into a −80°C freezer, where they would remain until 
needed for mRNA analysis. Upon removal from the freezer, 
the PVN area was punched. RNA was isolated using RNeasy 
plus Mini kits (Qiagen, CA, United  States) following 
manufacturer’ instructions. Following isolation, ~200  ng RNA 
from each sample was converted to cDNA in 20 μl PCR system 
using iScript cDNA synthesis kits (Bio-Rad), and the cDNAs 
were used as templates for real time PCR, which was performed 
to analyze mRNA levels of prepro-orexin (a precursor of OXA 
and OXB), OX1R, and AVP using gene specific TaqMan primers 
and probes. TaqMan primers were purchased from Fisher 
Scientific and were used in real-time PCR to measure mRNA 
levels of prepro-orexin (Hcrt), OX1R, AVP, and a housekeeping 
gene, GAPDH, which was used as an endogenous control. 
The manufacturer did not provide the detailed primer sequence 
information. The primer IDs were as follows: Hcrt: Rn00565995_
m1; OX1R: Rn00565032_m1; AVP: Rn00566449_m1; and 
GAPDH: Rn01775763_g1.
Immunostaining was performed to analyze OX1R, OXA, 
and AVP protein expression within the PVN as described 
previously (Huber et  al., 2017). Briefly, rats were deeply 
anesthetized using isoflurane. Once under deep anesthesia, cold 
phosphate buffer saline (PBS) followed by 4% paraformaldehyde 
(PFA) in 1xPBS was used to transcardially perfuse the animal. 
Following perfusion, the brain was removed and kept in 4% 
PFA overnight in 4°C. The next day, the brains were transferred 
and kept in 30% sucrose at 4°C until they sank to the bottom. 
Brains were then cut in 20-μm coronal sections using a cryostat. 
Brain sections containing the PVN area were then subjected 
to immunostaining. Following wash in 1xPBS 3 times for 
10  min each, brain sections were incubated with either rabbit 
anti-OX1R antibody (Alomon Laboratories, Jerusalem, Israel, 
1:300 dilution), rabbit anti-AVP antibody (OriGene Technologies, 
United  States, 1:400 dilution), or mouse anti-OXA antibody 
(Abcam, United  States, 1:300 dilution) in PBS containing 0.5% 
Triton X-100 and 5% horse serum for 72  h at 4°C. Following 
this incubation and 1xPBS washing, they were incubated 
overnight in secondary antibodies Alexa fluor 488 goat anti 
rabbit IgG (1:500), Alexa fluor 594 goat anti rabbit IgG (1:500), 
or Alexa fluor 594 donkey anti mouse IgG (1:500). Images 
representing immunofluorescence were taken with a Leica 
DMIL microscope.
Plasma AVP ELISA Testing
Rats were placed under heavy anesthesia using 5% isoflurane. 
They were then decapitated, and their blood was collected 
into the tubes coated with K2EDTA. The final EDTA 
concentration is ~1 mg/ml blood. The blood was then centrifuged 
at 4°C using an Eppendorf 5,804 R Centrifuge at 1,300 RPM 
for 30 min. The supernatant was extracted and stored in −80°C 
until use. Plasma AVP level were measured using Arg8-
Vasopressin Kit (Enzo Life Sciences, NY, United States) following 
the manufacturer’s instructions.
Data Collection
All rats subjected to PFA perfusion and subsequent 
immunostaining were unable to be  used for any physiological 
analysis other than protein immunofluorescence staining and 
blood pressure monitoring. However, all other animals subjected 
to brain and blood collection were utilized for multiple tests, 
including PCR and ELISA. Because of the overlap, and the 
multiple utilizations of one sample for various tests, some 
discrepancies in sample size may be  present. In general, an 
arbitrary sample size of 5~9, based on our previous work 
regarding the role of orexin and AVP in SSH (Huber et  al., 
2017), was chosen as a goal for each treatment group. In 
addition, all animals that were lost during surgery or before 
any measurements were taken, were not recorded, and were 
simply replaced, eliminating any effect on sample size.
Statistical Analysis
All data was analyzed using commercially available statistical 
software (SPSS 25.0, SPSS, Chicago). All data is expressed as 
mean  ±  SEM unless otherwise noted. Due to the directional 
nature of our hypothesis, and previous work from our lab, a 
one-tailed t-test was utilized to compare mean OX1R mRNA 
and AVP mRNA expression, as well as plasma AVP levels 
between control and DOCA-salt groups. Differences in mRNA 
expression and plasma concentrations between all three groups 
were analyzed using one-way ANOVA. If a significant interaction 
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was observed, Tukey post-hoc analysis was utilized to assess 
group differences. Individual blood pressure means were 
measured for each rat three times per week at week 1, and 
week 2 measurements, while only one measurement was taken 
during week 3. For each rat, the three weekly measurements 
were averaged, and then combined with the other rats in the 
respective group to obtain a weekly group average blood 
pressure. These weekly averaged blood pressures were compared 
to the baseline values for each group (recorded values 1  day 
prior to treatment). For blood pressure and heart rate (HR) 
data, a repeated measures ANOVA was performed with time 
as the within factor, and treatment condition as the between. 
If significance was observed, a Tukey post-hoc analysis was 
performed between groups. All values with a p  <  0.05 were 
considered significant.
RESULTS
DOCA-Salt Treatment Increases PVN 
OX1R Expression and Elevates Plasma 
AVP Levels
To assess whether OX1R expression was elevated in the PVN 
of DOCA-Salt rats, adult male SD rats were randomly divided 
into two groups. They were either subcutaneously implanted 
with a 75  mg, 21-day released DOCA pellet and received 
saline drinking water (1% NaCl and 0.2% KCl) or were subjected 
to sham surgeries and received regular drink water. Three 
weeks following DOCA-salt or sham treatment, rats were 
euthanized, and their brains were removed, and the PVN area 
was punched out and subjected to RNA isolation and subsequent 
real time PCR to measure OX1R mRNA expression. The results 
showed that PVN OX1R mRNA levels were significantly increased 
in the DOCA-salt treatment group (n = 4) compared to control 
animals [n  =  3; Figure  1A, Control: 1  ±  0 vs. DOCA-salt: 
1.2  ±  0.1, arbitrary units (a.u) *p  <  0.05].
Additionally, brain slices containing the PVN area were 
utilized to perform immunostaining using OX1R specific 
antibodies in order to visually assess any differences in receptor 
expression in the brains of control and DOCA-salt rats. It 
showed that DOCA-salt treatment increased OX1R 
immunoreactivity in the PVN (Figure  1B).
We further performed ELISA testing to investigate whether 
DOCA-salt treatment elicited an increase in plasma AVP 
concentrations. The results showed that, following 3-weeks of 
DOCA-Salt treatment, AVP plasma levels were significantly elevated 
in the DOCA-Salt rats (n  =  8) compared to control rats (n  =  4; 
Figure 2, Control: 9 ± 3 vs. DOCA-salt: 38 ± 9 pg/ml, *p < 0.05).
Chronic Knockdown of OX1R in the PVN 
Attenuates Hypertension Development in 
DOCA-Salt Rats
It is well established that DOCA-salt treatment can induce 
hypertension and increased AVP is implicated in this form of 
hypertension (Berecek et al., 1982a,b; Schenk and McNeill, 1992). 
Our aforementioned results indicate that DOCA-salt treatment 
results in a concurrent increase in both PVN OX1R expression 
as well as plasma AVP levels, indicating a potential causative 
role for orexin function in AVP secretion and hypertension 
development. In order to test the contribution of OX1R in 
the development of DOCA-salt hypertension, we  tested 
whether chronic knockdown of PVN OX1R can prevent 
hypertension development. Male, 8-week-old SD rats were 
divided into three groups: DOCA-salt, DOCA-salt+OX1R-
shRNA, and vehicle controls. Those in the DOCA-salt+OX1R-
shRNA group received bilateral PVN microinjection of 
AAV2-OX1R-shRNA. Following sufficient time to allow 
transgene expression, animals began either DOCA pellet 
implantation followed by saline water treatment, or sham 
surgery followed by regular tap water drinking as detailed 
in the Methods. Their blood pressure was measured via 
tail-cuff plethysmography. There were no significant 
differences in baseline blood pressure (Control: 118  ±  4 vs. 
DOCA-Salt: 116  ±  2 vs. OX1R-shRNA: 112  ±  4  mmHg, 
p > 0.05) or HR (Control: 306 ± 28 vs. DOCA-Salt: 341 ± 58 
vs. OX1R-shRNA: 278 ± 38 mmHg, p > 0.05) among groups. 
Our results showed that DOCA-salt treatment dramatically 
increased blood pressure, and chronic knockdown of PVN 
OX1R attenuated the observed increase in blood pressure 
induced by DOCA-salt treatment (Figure  3A). Specifically, 
a significant time  ×  condition effect on MAP was observed 
[F(6,30)  =  3.712, *p  <  0.05], indicating that there was 
differential MAP responsiveness over time among the three 
groups. There was also a significant group effect present 
[F(2,10) = 6.142, *p < 0.05], indicating that the MAP response 
to treatment in each experimental group was significantly 
different over the 3-week period. Post-hoc analysis showed 
a significantly higher MAP in the DOCA-salt treatment 
group (n  =  4) when compared to both the control (n  =  5; 
*p  <  0.05) and OX1R-shRNA (n  =  4; *p  <  0.05) groups. 
This effect was not observed in heart rate responses among 
groups [F(6,30)  =  0.837, p  >  0.05; Figure  3B].
We further compared OX1R mRNA expression in the PVN 
among the three groups of rats. There was a significant 
interaction between treatment condition and PVN OX1R 
mRNA levels [F(2,19)  =  6.168, *p  <  0.05]. Post-hoc analysis 
showed that DOCA-salt (n  =  10) treated rats showed an 
increase of approximately 35% in OX1R mRNA expression 
when compared to controls (n  =  7; Control: 1  ±  0.1 vs. 
DOCA-salt: 1.3 ± 0.1, a.u, p = 0.053). This effect was attenuated 
in OX1R-shRNA animals (n  =  5; OX1R-shRNA: 0.9  ±  0.1 
vs. DOCA: 1.3 ± 0.1, a.u, *p < 0.05). There were no significant 
differences between control and OX1R-shRNA animals 
(p  =  0.653; Figure  4A).
Similarly, control, DOCA-salt, and DOCA-salt+OX1R-shRNA 
animals’ brains were subjected to OX1R immunostaining as 
described previously to visually assess the adequacy of 
AAV-OX1R-shRNA in knocking down OX1R function. The 
mRNA results were similarly mirrored in immunostaining 
results shown in Figure  4B. The combination of these results 
indicates that our viral vector sufficiently knocked down OX1R 
expression in the PVN and decreased PVN OX1R attenuated 
DOCA-salt induced high blood pressure.
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Chronic Knockdown of PVN OX1R 
Reduces PVN AVP Expression and Partially 
Reduces Plasma AVP Levels
We further assessed the effect of chronic knockdown of PVN 
OX1R on AVP expression in the PVN. DOCA-salt treatment 
significantly increased PVN AVP expression and chronic 
knockdown of OX1R blocked the AVP increase induced by 
DOCA-salt treatment. Figure 5A shows the differences in PVN 
AVP expression between groups. There was a significant 
interaction between treatment condition and PVN AVP mRNA 
levels [F(2,19)  =  5.085, *p  <  0.05]. Post-hoc analysis showed 
that DOCA-salt (n  =  9) treated rats showed a significantly 
increased AVP mRNA when compared to controls (n  =  8; 
Control: 1  ±  0.3 vs. DOCA-salt: 3.1  ±  0.8, a.u, *p  <  0.05). 
However, this effect was attenuated in OX1R-shRNA animals 
(n  =  5; OX1R-shRNA: 0.6  ±  0.3 vs. DOCA: 3.1  ±  0.8, a.u, 
*p < 0.05). There were no significant differences between control 
and OX1R-shRNA animals (p  >  0.05).
We further measured and compared plasma AVP levels of 
the three groups of rats to assess whether the observed increase 
in PVN production of AVP translated to increased peripheral 
circulation of AVP. ANOVA analysis revealed a significant 
difference in plasma AVP levels between groups [F(2,13) = 7.02, 
*p  <  0.05]. Post hoc analysis revealed that DOCA-salt (n  =  5) 
treated rats presented a significantly increased plasma AVP 
concentration when compared to controls (n  =  6; Control: 
6  ±  1 vs. DOCA-salt: 20  ±  4  pg/ml, *p  <  0.05). Additionally, 
OX1R-shRNA rats (n  =  5) had a partially attenuated plasma 
AVP level (11 ± 2 pg/ml) compared to DOCA-salt rats, although 
this relationship only trended toward significance (p  =  0.077; 
Figure  5B).
Consistent with this finding in AVP mRNA expression and 
plasma AVP, immunostaining showed that DOCA-salt treatment 
drastically increased AVP immunoreactivity in the PVN, and 
chronic knockdown of OX1R in the PVN blocked DOCA-salt 
induced increases in PVN AVP protein expression Figure  5C.
DISCUSSION
Hypertension is a major health concern that currently impacts 
a large majority of the general population. Despite its 
A
B
FIGURE 1 | Deoxycorticosterone acetate (DOCA)-salt treatment increases orexin 1-receptor (OX1R) expression in the paraventricular nucleus (PVN) of 
Sprague Dawley (SD) rats. OX1R mRNA (A) and immunofluorescence (B) was compared in the PVN area between DOCA-salt treated (n = 4) and vehicle 
control (n = 3) rats. DOCA-salt treated rats showed a significant increase in OX1R expression within the PVN area (*p < 0.05). PVN, paraventricular nucleus; 
OX1R, orexin 1-receptor.
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widespread prevalence, treatment options are not always 
sufficient to combat its detrimental impacts on an individual’s 
health. Furthermore, around half of those individuals 
diagnosed with hypertension are estimated to be  classified 
as salt-sensitive (Weinberger et  al., 1986; Weinberger, 1996). 
To this end, the present study sought to assess the role 
that orexin system hyperactivity may hold in the development 
of hypertension in the DOCA-salt hypertensive rat. We report 
four novel findings: (1) OX1R expression within the PVN 
of DOCA-salt rats is elevated compared to controls; (2) 
Chronic viral knockdown of OX1R function within the PVN 
of DOCA-salt rats reduces PVN AVP mRNA and protein 
expression; (3) Chronic viral knockdown of PVN OX1R 
function results in an attenuated plasma AVP concentration; 
and (4) The development of hypertension is significantly 
attenuated in the DOCA-salt rat following PVN OX1R 
knockdown. These results lead us to conclude that high 
salt intake causes activation of the CVOs. From here, neural 
projections are sent to cardiovascular relevant regions such 
as the PVN (Kawano and Masuko, 2010), in addition to 
A
B
FIGURE 3 | Chronic knockdown of OX1R in the PVN attenuates increased mean arterial pressure (MAP) induced by DOCA-salt treatment in SD rats. Rats were 
bilaterally injected with AAV2-OX1R-shRNA into the PVN 2 weeks prior to DOCA-salt treatment. Following this, blood pressure was monitored for 3 weeks during 
DOCA-salt treatment. Central knockdown of OX1R (n = 4) within the PVN results in attenuation of mean arterial pressure compared to DOCA-salt treated rats (n = 4; 
A; *p < 0.05), while there was no difference between OX1R knockdown rats and controls (n = 5). OX1R knockdown within the PVN had no impact on heart rate 
between groups (B; p > 0.05). MAP, mean arterial pressure; HR, heart rate.
FIGURE 2 | Deoxycorticosterone acetate-salt treatment significantly 
increases plasma arginine vasopressin (AVP) concentrations in SD rats. 
Following 3 weeks of DOCA-salt treatment or vehicle control, ELISA 
analysis was performed on the plasma of DOCA-salt (n = 8) and vehicle 
control (n = 4) rats to confirm the effectiveness of DOCA-salt treatment in 
causing increased plasma AVP. DOCA-salt rats showed a significantly 
increased plasma AVP concentration (*p < 0.05). AVP, arginine 
vasopressin.
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the lateral hypothalamus (LH; Hahn and Swanson, 2010; 
Hurley and Johnson, 2014). These projections may directly 
and indirectly induce orexin A release to the PVN area. 
Upon binding with OX1R in the PVN, AVP production is 
stimulated, ultimately leading to the development of 
hypertension through numerous downstream physiological 
responses (vasoconstriction, fluid reabsorption, etc.; Figure 6). 
Furthermore, this effect can be  significantly attenuated 
following OX1R knockdown in the PVN.
Arginine vasopressin plays a key role in physiological 
homeostatic regulation through interaction with its various 
receptor subtypes (V1, V2, and V3). Relevant to the current 
study, AVP interacts with V1 and V2 receptors to regulate 
smooth muscle vasoconstriction, and water reabsorption through 
reallocation of aquaporins in the collecting ducts of the kidneys 
(Thibonnier et  al., 1998; Bankir et  al., 2005; Treschan and 
Peters, 2006). Upon binding, downstream signaling cascades 
are activated, resulting in a net increase in blood pressure 
through vasoconstriction and volume retention. Importantly, 
AVP production within the PVN magnocellular neurons is 
initiated following a salt load due to interactions with 
circumventricular organs, implicating its actions in the 
pathogenesis of salt-sensitive hypertension. Furthermore, AVP 
has been observed to play a role in both Dahl-salt sensitive 
hypertension, in addition to DOCA-salt hypertension (Berecek 
et  al., 1982a; Schenk and McNeill, 1992; Grillo et  al., 1998; 
Huber et  al., 2017). Interestingly, OX1R expressing neurons 
are co-localized with AVP producing neurons within the PVN 
(Backberg et al., 2002), indicative of some level of communication 
between the two mechanisms. Similarly, recent research from 
our lab (Huber et  al., 2017) and others (Hernandez et  al., 
2018) has shown increased orexin system activity in both 
Dahl-salt sensitive and DOCA-salt rats.
The present study observed an increase in both central 
and peripheral AVP following DOCA-salt treatment, as would 
be expected. However, we also observed a concurrent increase 
in OX1R expression within the PVN, indicating a simultaneous 
increase in orexin activity and AVP production. To date, 
we are only aware of one other study that has assessed orexin 
system components’ expression in the DOCA-salt model 
(Hernandez et al., 2018). However, our previous work observed 
an increase in PVN AVP production following ICV injection 
of orexin-A (Huber et  al., 2017), supporting the causative 
role of orexin signaling in AVP production and release to 
the periphery. As OXA has a higher binding affinity for OX1R, 
which is concentrated in the PVN, we  posit that our results 
A
B
FIGURE 4 | Paraventricular nucleus bilateral microinjection of AAV2-OX1R-shRNA significantly reduces OX1R expression within the brain. Following 3 weeks of 
DOCA-salt treatment, rat PVN areas were collected and subjected to either PCR analysis or immunostaining. mRNA levels of OX1R (A) were significantly reduced 
following OX1R knockdown (n = 5; *p < 0.05) compared to DOCA-salt treated rats (n = 10). There were no significant differences between OX1R knockdown rats 
and controls (n = 7; p > 0.05). These results were further supported by immunostaining analysis (B). PVN, paraventricular nucleus; OX1R, orexin 1-receptor.
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were primarily mediated through activation of the OX1R. 
This is indicative of a causative role of OXA binding in both 
the production, and systemic release of AVP which may point 
to a common pathway pertinent to SSH development. The 
increased orexin system components observed in the DOCA-
salt rats, paired with increased AVP production following 
OXA ICV injection in normal SD rats (Huber et  al., 2017) 
lends credence to our hypothesis that OXA-OX1R interactions 
facilitate increased AVP production and release. To further 
elucidate the modulatory role of orexin activity on AVP 
production and release, we  injected an OX1R-shRNA viral 
vector, which effectively reduced OX1R expression within the 
PVN. In line with our hypothesis, this viral knockdown 
resulted in a concurrent decrease in PVN AVP expression, 
and release to the periphery. These findings outline the key 
role of OX1R in regulation of AVP production and release 
following a high-salt load in DOCA-salt rats. We  elected not 
to test OX2R function in this model after previous work 
observed no impact of OX2R antagonism on AVP mRNA in 
primary neuronal cultures treated with OXA (Huber et al., 2017).
Orexin activity has been shown to play a key role in blood 
pressure regulation (Samson et  al., 1999; Shirasaka et  al., 1999; 
Schwimmer et  al., 2010). Furthermore, antagonism of orexin 
through various means results in an attenuation of its pressor 
effects (Marques et  al., 2011; Lee et  al., 2013; Li et  al., 2013; 
Huber et  al., 2017). Indeed, microinjection of AVP elicits a 
similar increase in sympathetic outflow, while antagonism of 
the V1 receptor in the PVN attenuates SNA outflow and 
hypertension in high-salt intake rats (Ribeiro et  al., 2015). In 
the DOCA-salt rat model, the hypertensive response is marked 
by an initial steep spike in blood pressure, followed by a more 
gradual increase and maintenance in the weeks following DOCA 
administration (Yemane et  al., 2010). While there are some 
discrepancies in the etiology regarding the magnitude of impact 
in sympathetic outflow and DOCA-Salt hypertension 
development (de Champlain et  al., 1968; Bouvier and de 
Champlain, 1986; Yemane et  al., 2010), we  elected to focus 
primarily on AVP as the key regulator, given its established 
role in the model. Our results observed the expected gradual 
increase in blood pressure for the 3-week period following 
DOCA-salt administration. However, chronic viral knockdown 
of PVN OX1R function attenuated the pressor response normally 
observed in the DOCA-salt rat model. Interestingly, it appeared 
as though the steep increase, as well as maintenance periods 
were equally dampened. While this may indicate some impact 
on sympathetic outflow, we  cannot speak to this as we  did 
not directly record nerve activity. However, Huber et al. (2017) 
previously observed that bilateral PVN microinjection of 
SB-408124, an OX1R antagonist, did not impact SNA outflow 
in Dahl-Salt sensitive rats, although it did drastically decrease 
mean arterial pressure in an acute setting. This relationship 




FIGURE 5 | Paraventricular nucleus bilateral microinjection of AAV2-OX1R-shRNA significantly reduces central production and subsequent peripheral release of 
AVP. Following 3 weeks of DOCA-salt treatment, brain PVN areas as well as plasma were collected to test AVP central expression and peripheral secretion. PVN 
OX1R knockdown (n = 5) resulted in a significantly reduced PVN AVP mRNA expression (A) compared to DOCA-salt treated rats (n = 9; *p < 0.05), but not control 
rats (n = 8; p > 0.05). Similarly, OX1R knockdown in the PVN (n = 5) appeared to partially reduce plasma AVP levels compared to DOCA-salt rats (n = 6; B), 
although this did not reach significance (p = 0.077). OX1R knockdown rats showed no differences in plasma AVP levels when compared to control rats (n = 6; 
p > 0.05). Lastly, immunostaining revealed a reduced protein expression of AVP in the PVN area following OX1R knockdown (C). PVN, paraventricular nucleus; AVP, 
arginine vasopressin.
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hypertension, specifically through modulation of AVP rather 
than sympathetic outflow. Our results confirm these at a chronic 
level, showing that viral knockdown of OX1R resulted in 
attenuation, but not complete amelioration, of hypertension 
development in DOCA-salt rats. While we cannot entirely rule 
out long-term modulation of sympathetic outflow, we  presume 
that this attenuation occurred through the observed chronic 
attenuation of AVP production and release, and subsequent 
downstream activity. Further research utilizing sympathetic 
nerve recordings should be utilized to discern the impact orexin 
may have on sympathetic outflow in the DOCA-salt rat model.
It is worth noting the potential impact that other physiological 
systems may have had in preventing complete elimination of 
hypertension development. The RAS is a well-known hormonal 
blood pressure regulatory mechanism, and central RAS 
functioning, specifically in the PVN, has been shown to play 
a role in blood pressure regulation (Jensen et al., 1992; Bahner 
et  al., 1995; Zhu et  al., 2002; Chen et  al., 2011). Angiotensin 
II (ANGII) receptors are densely localized in the PVN area 
(Pan, 2004), with some studies noting a higher consolidation 
of AT1 Receptors within parvocellular (pre-autonomic), rather 
than magnocellular PVN neurons (Lenkei et al., 1995; Oldfield 
et  al., 2001). PVN microinjection of ANGII elicits a pressor 
effect presumably through both activation of sympathetic activity, 
as well as AVP release (Tsushima et  al., 1994; Zhu et  al., 2002; 
Khanmoradi and Nasimi, 2016). In the DOCA-salt rat model, 
increased ANGII receptor concentrations and binding have 
been observed within the PVN (Gutkind et al., 1988). Similarly, 
ANGII is elevated within the cerebrospinal fluid in the DOCA-
salt rat model (Basting and Lazartigues, 2017). It is possible 
in our model that central ANGII activity may have had a 
role in the slight increase in blood pressure observed in our 
results. Our results show a significant dampening of blood 
pressure elevation following OX1R PVN antagonism, indicating 
that this pressor response may have been mitigated, at least 
in part, through the observed indirect reduction of AVP 
production through OX1R antagonism. Interestingly, despite a 
presumed intact effect of ANGII on parvocellular neurons and 
their subsequent innervation of pre-autonomic neurons, we did 
not observe a significant increase in blood pressure following 
PVN OX1R knockdown. This may be  indicative of a lack of 
global sympathetic outflow in our specific model, which omits 
uninephrectomy (Kandlikar and Fink, 2011).
Similarly, neuroinflammation may have played a key role in 
the slight blood pressure increase in the OX1R knockdown rats. 
PICs have been observed to have an indirect impact on neural 
inflammatory responses through interactions with CVOs (Zhang 
et  al., 2003; Wei et  al., 2013, 2015), similar to the pathways 
utilized by ANGII. Central administration of proinflammatory 
cytokines, including Tumor Necrosis Factor alpha and Interleukin 
1-Beta have caused a pressor response in normal SD rats (Shi 
et  al., 2011; Wei et  al., 2015). Research from our own lab has 
reported that proinflammatory cytokine expression is elevated 
in Dahl-Salt sensitive rats (Jiang et al., 2018). Further, we observed 
that OXA intracerebroventricular injection elicits substantial 
elevations in inflammation within the PVN (Fan et  al., 2018), 
in addition to increased sympathetic outflow. However, we found 
that PVN injection of the OX1R antagonist, SB408124, significantly 
attenuated the sympathetic response to OXA (Fan et  al., 2018). 
Our current findings may be  in part due to a reduced 
neuroinflammatory response resulting from chronic OX1R 
downregulation. However, the DOCA-salt model is also marked 
by peripheral renal inflammation (Banek et  al., 2019), which 
may have aided in the slightly elevated blood pressure despite 
central PVN OX1R knockdown. Unfortunately, we  did not 
monitor central or peripheral inflammatory markers, and cannot 
elaborate on the role they may have played in the current study.
Additionally, we did not assess the influence of AVP production 
within the Supraoptic Nucleus (SON). The SON is a major 
area of AVP production (Treschan and Peters, 2006), and OX1R 
expressing neurons are co-localized with vasopressin producing 
neurons in this area (Backberg et  al., 2002). The lack of OX1R 
knockdown within the SON may account for the partial blood 
pressure increase in the PVN OX1R knockdown rats. Further, 
this may also explain why we  did not observe a significantly 
blunted plasma AVP release following PVN OX1R knockdown, 
as AVP from the SON may have been released to the periphery.
FIGURE 6 | The hypothesized relationship mediating the impact of central 
orexin system functioning on hypertension development in the DOCA-salt rat 
model. DOCA-salt treatment results in activation of circumventricular organs 
(CVOs), which send projections to the lateral hypothalamus (LH), stimulating 
Orexin A (OXA) release. OXA then interacts with OX1R at the PVN. This then 
facilitates an increased production and secretion of AVP to the periphery, where 
it causes increased blood pressure through various means including 
vasoconstriction, fluid reabsorption, and increased blood volume. CVO, 
circumventricular organs; LH, lateral hypothalamus; OXA, orexin-A; OX1R, 
orexin 1-receptor; PVN, paraventricular nucleus; and AVP, arginine vasopressin.
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There are a few reasons why DOCA-salt treatment may activate 
the CVOs in our hypothesized model. First, increased plasma 
NaCl or increased osmolality may activate osmoreceptors located 
in the Organum Vasculosum of the Lamina Terminalis (OVLT) 
and the Subfornical Organ (SFO), which have projections to both 
the LH and PVN (Hahn and Swanson, 2010; Kawano and Masuko, 
2010; Hurley and Johnson, 2014). Through this mechanism, 
signaling from the CVOs to the lateral hypothalamus may stimulate 
OXA release to the PVN, where it interacts with OX1R to elicit 
increased AVP production. Indeed, OVLT lesion partially attenuates 
the hypertensive response in DOCA-salt rats (Collister et  al., 
2018). Further, normalization of central and peripheral NaCl levels 
in DOCA-salt treated rats results in reduced blood pressure and 
sympathetic outflow (O’Donaughy and Brooks, 2006; O’Donaughy 
et  al., 2006), while this was not observed in sham animals, 
signifying a key role for plasma NaCl in hypertension development. 
Second, circulating mineralocorticoids may directly impact activation 
of CVOs, since mineralocorticoid receptors are densely located 
in osmosensitive regions of the brain (Pietranera et  al., 2004; 
Amin et  al., 2005; Miller et  al., 2013). Third, there is evidence 
that there may be  synergistic activation of CVOs through both 
increased NaCl and circulating mineralocorticoids. Chronic DOCA 
treatment has been observed to augment the effects of increased 
NaCl, as decreasing circulating NaCl in DOCA-salt rats resulted 
in a greater blood pressure decrease when compared to rats treated 
with either DOCA or salt alone (O’Donaughy and Brooks, 2006). 
Evidence points toward cooperative activation of CVOs by both 
elevated NaCl and DOCA, which in turn send projections to 
both the lateral hypothalamus and PVN, potentially stimulating 
orexin system activity. However, we did not directly test the effect 
of CVO activation, and further efforts are necessary to validate 
our hypothesis.
The current study does yield some limitations. First, we elected 
not to perform a uninephrectomy in addition to the DOCA-salt 
treatment, as is often observed. However, we  followed the 
previously established model exemplified by Kandlikar and Fink 
(2011), where uninephrectomy was not utilized in order to create 
a more gradual increase in blood pressure which more closely 
mimics that observed in human hypertension development. 
Furthermore, omitting the uninephrectomy allows us to better 
assess the direct impacts of orexin modulation by removing 
any of the cardiovascular implications that kidney removal incurs. 
Next, we recognize that the tail-cuff method is not the preferred 
standard of blood pressure measurement. Due to time and cost 
constraints, we  were unable to perform radio telemetry 
measurements directly from arterial vessels. However, Feng et al. 
(2008) observed an adequate level of agreement between telemetry 
and tail-cuff blood pressure measurements, adding validity to 
our observed measurements. Additionally, we  did take every 
precaution we could in order to reduce the stress on the animals 
while taking measurement (see Materials and Methods). 
Furthermore, we  used the average of the weekly values for the 
first 2  weeks following DOCA-salt implantation, which reduces 
the error and deviations of daily measures. Further research 
should be conducted to repeat these findings using radio telemetry. 
We  also recognize the importance of sex differences in blood 
pressure regulation. While we  did not study females in this 
study, this also offers a future direction that requires exploration. 
Lastly, we note that use of a scrambled shRNA (AAV-Sc-shRNA) 
in addition to our AAV2-OX1RshRNA would strengthen our 
findings. However, in our previous unpublished data, in addition 
to a number of publications by Sun et  al. (2008), scrambled 
AAV-Sc-shRNA injections were found to have no impact on 
blood pressure or other physiological parameters (Wang et  al., 
2012; Crosswhite et  al., 2014; Chen and Sun, 2017). Because 
of these findings, we did not include an AAV-Sc-shRNA treatment 
group, although we do recognize that addition of a sham control 
would increase the rigor of the present study. Further studies 
are necessary to confirm our observed results.
In conclusion, our results indicate a key role for orexin in 
the development of SSH in the DOCA-salt rat model. 
We  conclude that DOCA implantation paired with salt intake 
in SD rats results in heightened orexin system activation, 
primarily through OXA-OX1R binding. This heightened orexin 
activity then stimulates increased production of AVP within 
the PVN, and subsequent release to peripheral circulation, 
ultimately leading to the development of hypertension. This 
work furthers the role of orexin involvement in the pathogenesis 
of SSH and offers a potential mechanism that may be  useful 
in eventual development of a pharmaceutical intervention to 
combat the negative impact of hypertension.
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